Juan M. Goni-Ramos

Klimmen, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

An exploratory analysis of interaction effects in EQ-5D valuation using saturated EQ VAS datasets from the Netherlands, the United Kingdom, and China.

An exploratory analysis of interaction effects in EQ-5D valuation using saturated EQ VAS datasets from the Netherlands, the United Kingdom, and China.

Journal: Health and quality of life outcomes

Published: January 12, 2026

Health State Utility Values Associated with Knee Osteoarthritis: A Vignette-Based Approach.

Health State Utility Values Associated with Knee Osteoarthritis: A Vignette-Based Approach.

Journal: Patient preference and adherence

Published: August 20, 2025

Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States.

Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: August 06, 2025

Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children.

Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children.

Journal: PharmacoEconomics

Published: July 27, 2025

Design and implementation of data quality controls in the EQ-DAPHNIE study: insights from the pilot phase and 15-country analysis.

Design and implementation of data quality controls in the EQ-DAPHNIE study: insights from the pilot phase and 15-country analysis.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: May 26, 2025

EuroQol data for assessment of population health needs and instrument evaluation (EQ-DAPHNIE): a study for enhancing population health assessment.

EuroQol data for assessment of population health needs and instrument evaluation (EQ-DAPHNIE): a study for enhancing population health assessment.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: April 21, 2025

Health-related quality of life and QALY loss under COVID-19 lockdown: The case of Spain.

Health-related quality of life and QALY loss under COVID-19 lockdown: The case of Spain.

Journal: PloS one

Published: January 29, 2025

Testing the Valuation of the EQ-5D-Y-5L in Adults and Adolescents: Results From a 5-Country Study and Implications for the Descriptive System.

Testing the Valuation of the EQ-5D-Y-5L in Adults and Adolescents: Results From a 5-Country Study and Implications for the Descriptive System.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2024

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.

Journal: PharmacoEconomics - open

Published: August 22, 2024

Correction: Valuation of the EQ-5D-5L in Taiwan.

Correction: Valuation of the EQ-5D-5L in Taiwan.

Journal: PloS one

Published: June 18, 2024

An Acquired Taste: Latent Class Analysis to Compare Adolescent and Adult Preferences for EQ-5D-Y-3L Health States.

An Acquired Taste: Latent Class Analysis to Compare Adolescent and Adult Preferences for EQ-5D-Y-3L Health States.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: April 10, 2024

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".

Journal: Dermatology and therapy

Published: January 22, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026